{"name":"Sciwind Biosciences","slug":"sciwind","ticker":"Private","exchange":"Private","domain":"sciwindbiosciences.com","description":"Sciwind Biosciences is a private biopharmaceutical company focused on developing innovative treatments for obesity and metabolic diseases. The company has a pipeline of promising candidates, including its lead asset, which is currently in Phase 3 clinical trials. Sciwind Biosciences is well-positioned to capitalize on the growing demand for effective obesity and metabolic disease treatments. With a strong pipeline and a focus on innovation, Sciwind Biosciences is an exciting company to watch in the biopharmaceutical space.","hq":"Shanghai, China","founded":0,"employees":"","ceo":"Frank (Xiaofeng) Zhong","sector":"Obesity / Metabolic Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$1.5B (private valuation)","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"SB-4800 patent cliff ($0.00 at risk)","drug":"SB-4800","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oral ecnoglutide tablet","genericName":"Oral ecnoglutide tablet","slug":"oral-ecnoglutide-tablet","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"XW003","genericName":"XW003","slug":"xw003","indication":"Treatment of type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Oral ecnoglutide tablet","genericName":"Oral ecnoglutide tablet","slug":"oral-ecnoglutide-tablet","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"XW003","genericName":"XW003","slug":"xw003","phase":"phase_3","mechanism":"XW003 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Sciwind Biosciences Announces FDA Clearance of IND for Phase 3 Clinical Trial of SB-4800","summary":"Sciwind Biosciences announced that the FDA has cleared the Investigational New Drug (IND) application for its Phase 3 clinical trial of SB-4800, a novel treatment for obesity.","drugName":"SB-4800","sentiment":"positive"},{"date":"2023-09-01","type":"deal","headline":"Sciwind Biosciences Raises $100M in Series C Funding","summary":"Sciwind Biosciences announced that it has raised $100 million in Series C funding to support the development of its pipeline, including its lead asset SB-4800.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPYVFQT0syZ2szbkhHMHk2ZE9ZNXlXcWQzelNwcjFxY3ZCaFEzZWF4QXZEM1I4TkgyYVppNm5pdzNqRDBYM2FMOU5DVVByLXYwQ2xNcXdabEZ1TmtEdjZYNFl6azhyaWJlb0pjS2VTbWVINjBwWGpBWGRHS0dSdjN4Z0prZXd5aEV6aHFtY1RPZ2loM01rR3BfaEJnUFR3NEdFSm10U3pPcnFxNkFoR2NPSHZiN0pHRGt0UkE?oc=5","date":"2026-02-24","type":"deal","source":"Forbes","summary":"Pfizer Adds Sciwind As China Partner For New Weight Loss Drug - Forbes","headline":"Pfizer Adds Sciwind As China Partner For New Weight Loss Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQeUJraXdwWFk5blItSy1EWjFpVkR6d0Y0R3BJV3pGS29pMXN5RkhIYVA2U2NXV3FjaDBEZXNYR2FPTTNCbzhNbXhRdEhqWU5jWXZVckNEVW1TYnBueXlxdFZwcHFNZm1vN2g1VjZSTnhNZV9mZUZQSGYzWkpvOGwzRnVhODg2VEpnQ0JIQ1hRQmtqRG8ybnpPSWtSZnkyV2hpbUpxUzREazdjRHp3UTdRZGtkQ1g5dFROZHVRbmtn?oc=5","date":"2026-02-24","type":"regulatory","source":"Fierce Pharma","summary":"Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China - Fierce Pharma","headline":"Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNRzdOSk9QYjdPQlBFbFItbmpMU09FcktoeGlvdW5oay1taG1PNnhpRnpwamxlRV9hU0NsRXEtR1dNZ05mY0VTRHUwR0U3cVc5RGZUQ2VPNmlNN2JzaUVWMVNjeU51Y2htTE9KaHJrSUdmM19acjZvcE5pTXVDazRNRHhOWW03SHYyZTMtMW5jSlVYa3drVUhWMnZteGRWWVRYYUFIeTN4NXczYWV4TkIyTGpWN3V6NGFhdkp1c3p4YTZGZjJCOEV6eUc3OU16UTJtaHRzOWd6VzZBSmE4bExfSmd0R3g0QWlZTFRrS3kzN1Z3aGwtbi1xT0dKWUNGNXdKTE80?oc=5","date":"2025-09-05","type":"pipeline","source":"PR Newswire UK","summary":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOWnYxTWNfQXoxaDl3eUdtRHY4T214Ukw2NmZRekxTM2ZHcGVnWGo2cm5jckxLMGVoRUxKbXJ6dVNxSXQ2dE90M2NIZjFxWXNiOVRUbkhVRDRTdlBPT091dkJacTl3V09LUWNISE14bWxxUE5KQTJqTE1wSGJ3N3R1UmM4TUZEbUU5MmR3aGVsVjFwdWp3TGxycHp3?oc=5","date":"2025-04-30","type":"earnings","source":"Pharmaceutical Technology","summary":"Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution - Pharmaceutical Technology","headline":"Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5UdUhKZ0V6NlB1d1VpM2ttMmdPQzFTeG5QRFpJaklPaVF6ZElSeUdrajlDalVwYlZXREN1bWx2MkJBdTZNLS1lN2xUNHVORkR4UXFFaGRFMnNMdnZxRUtEM0VnM1lvby1seGRhTzM3bWxsaFctX0R3UA?oc=5","date":"2025-02-08","type":"pipeline","source":"PharmTech.com","summary":"Next-Generation Anti-Obesity Medicines - PharmTech.com","headline":"Next-Generation Anti-Obesity Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQVWxoTVRPV2R4SlNac25BUFZmbTNVaHNHWGNfY0ppX2FieVpSbHZnVUV1WHlUTUZ4MmVWQWtzb2hsWG1EMmZwR3hGOHNCU29HNXgxeGI0ckU4T0lHdURURktST1pPZm9QQVpHWVRZMW1zWmNFVDZRYi1UWF9TV3ZLM1ZXa3RZMThwYXpldFBGemQ2a2ZyYU83dkUtb2lKanB3ckhpcmpHUjR3UzM2VGdDNXRDWQ?oc=5","date":"2025-01-09","type":"pipeline","source":"Pharmaceutical Technology","summary":"UK-based Verdiva launches with $410m and an oral GLP-1RA candidate - Pharmaceutical Technology","headline":"UK-based Verdiva launches with $410m and an oral GLP-1RA candidate","sentiment":"neutral"}],"patents":[{"drugName":"SB-4800","drugSlug":"sb-4800","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novo Nordisk","Eli Lilly","Merck & Co."],"therapeuticFocus":["Obesity","Metabolic Disease"],"financials":null,"yahoo":null}